Varex Imaging offers a statistically high-asymmetry setup (4.46 ratio, 47.6% modeled upside) riding a strong earnings beat streak, but a death-cross hard block, a quality score below the engine's floor, and thinly covered analyst sentiment keep the setup speculative.
Thesis pillars
- High Asymmetry Earnings Catalyst Setup→Stable
- Quality Below Floor On Cash Burn→Stable
- Death Cross Hard Block Despite Recovery Signs→Stable
- +2 more pillars — see the Why tab for full reasoning
Varex Imaging Corporation (VREX) Stock Analysis
Recovery setup · Catalyst-Driven edge
Healthcare · Medical Devices
Sell if holding. Engine safety override at $10.91: Quality below floor (3.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10 and A.R:R 3.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend.
Varex Imaging designs and manufactures X-ray imaging components — X-ray tubes, flat panel and photon-counting detectors, linear accelerators, and imaging software — sold to OEM customers through its Medical and Industrial segments, with about 2,400 employees across North... Read more
Sell if holding. Engine safety override at $10.91: Quality below floor (3.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10 and A.R:R 3.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 58. Score 6.0/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 23d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
About Varex Imaging Corporation
About Varex Imaging Corporation
Varex Imaging's largest customer, Canon Medical Systems, accounted for 18% of fiscal 2025 revenue, while its ten largest customers together made up roughly 52%. The company employs approximately 2,400 people across manufacturing and engineering sites in North America, Europe, and Asia, split between Medical and Industrial segments that design, build, and service X-ray tubes, detectors, and imaging systems.
Varex sells X-ray tubes, flat panel and photon counting detectors, linear accelerators, and imaging software primarily to OEM customers that design the components into medical, security, and industrial inspection systems, then depends on replacement and service revenue as tubes and detectors wear out — CT tubes typically every 2 to 6 years, and as often as every 10 to 20 months in China given high equipment utilization. The company competes against in-house X-ray tube production at major diagnostic imaging companies such as Canon and Philips Healthcare, as well as against detector makers including Trixell, Vieworks, Hamamatsu, and iRay Technology. Manufacturing spans eight countries, including the United States, Germany, and the Philippines, with certain components — transistor arrays and cesium iodide coatings for digital detectors, and specialized X-ray tube targets among them — sourced from a limited group of suppliers or a single source. Revenue from customers outside the United States made up 70% of total fiscal 2025 revenue.
Show full overview
Varex's China exposure illustrates a risk distinct from customer concentration: medical X-ray tubes imported into China made up 10% of total revenue in fiscal 2025, and in April 2025 China's Ministry of Commerce opened MOFCOM investigations into US-origin CT X-ray tubes and tube inserts, before suspending both indefinitely in November 2025. Should the investigations resume and result in new tariffs, Varex has cautioned that its export prices to China may no longer compete with local manufacturers. The company also holds joint-venture stakes — including a 40% interest in dpiX, its amorphous-silicon detector-array supplier, and a 75% stake in Varex Imaging Arabia — that have drawn shareholder disputes and litigation in Germany since 2023.
See also: Healthcare · Medical Devices
From Varex Imaging Corporation's most recent 10-K filing, extracted July 6, 2026.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Unprofitable operations — net margin -9.6%. Quality floor flags this regardless of sector context.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $10.91: Quality below floor (3.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10 and A.R:R 3.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 58. Prior stop was $10.15. Score 6.0/10, moderate confidence.
Take-profit target: $15.66 (+43.5% upside). Prior stop was $10.15. Stop-loss: $10.15.
Quality below floor (3.3 < 4.0).
Varex Imaging Corporation trades at a P/E of N/A (forward 10.1). TrendMatrix value score: 9.0/10. Verdict: Sell.
11 analysts cover VREX with a consensus score of 4.2/5. Average price target: $18.
What does Varex Imaging Corporation do?Varex Imaging designs and manufactures X-ray imaging components — X-ray tubes, flat panel and photon-counting...
Varex Imaging designs and manufactures X-ray imaging components — X-ray tubes, flat panel and photon-counting detectors, linear accelerators, and imaging software — sold to OEM customers through its Medical and Industrial segments, with about 2,400 employees across North America, Europe, and Asia. The company's largest customer, Canon Medical Systems, accounted for 18% of fiscal 2025 revenue, and its ten largest customers together made up roughly 52%. Long design-in relationships with OEMs, some spanning over 35 years, create switching costs that favor Varex's incumbency in replacement compone